| Bioactivity | Glibornuride is a blocker of ATP-sensitive K+ channels (KATP channel) with a pKi of 5.75[1]. Antidiabetic agent[2]. | ||||||||||||
| Target | pKi: 5.75 (KATP channel) | ||||||||||||
| In Vivo | Administration of Glibornuride (5 mg/kg; gavage, daily for 28 days) for 28 days causes an increase in body weights in the diabetic groups in Swiss albino rats[2].Treatment with Glibornuride for 28 days decreases the serum uric acid levels in diabetic rats[2].Administration of Glibornuride for 28 days, insignificantly increases the liver lipid peroxidation levels in diabetic rats[2]. Animal Model: | ||||||||||||
| Name | Glibornuride | ||||||||||||
| CAS | 26944-48-9 | ||||||||||||
| Formula | C18H26N2O4S | ||||||||||||
| Molar Mass | 366.48 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Löffler C, et al. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta. Br J Pharmacol. 1997 Feb;120(3):476-80. [2]. Ozsoy-Sacan O, et al. Effects of parsley (Petroselinum crispum) extract versus Glibornuride on the liver of streptozotocin-induced diabetic rats. J Ethnopharmacol. 2006 Mar 8;104(1-2):175-81. |